Additional genetic alterations widely reported in the literature are now considered in the refined classification of high-grade gliomas, such as mutations in TP53 and ATRX and EGFR amplification, further underscoring the predominant role of tumor genetics [21,22,23]. This evidence concerns the gene EGFR and central nervous system cancer.